YB-1 immunization combined with regulatory T-cell depletion induces specific T-cell responses that protect against neuroblastoma in th

Acta Biochimica et Biophysica Sinica

Volumn 44, Issue 12, 2012, Pages 1006-1014

  Zheng, J ^a   Liu, P ^a   Yang, X ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

CD25; immunization; neuroblastoma; YB 1

Indexed keywords

GAMMA INTERFERON; TRANSCRIPTION FACTOR; YB 1 PROTEIN, MOUSE; YB-1 PROTEIN, MOUSE;

ADOPTIVE IMMUNOTHERAPY; ANIMAL; ARTICLE; CANCER STAGING; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENETICS; IMMUNIZATION; IMMUNOLOGY; LYMPHOCYTE DEPLETION; METABOLISM; METHODOLOGY; MORTALITY; MOUSE; MOUSE STRAIN; NEUROBLASTOMA; REGULATORY T LYMPHOCYTE; SPLEEN; SURVIVAL RATE; T LYMPHOCYTE; TIME; TRANSPLANTATION; TUMOR CELL LINE; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; IMMUNIZATION; IMMUNOTHERAPY, ADOPTIVE; INTERFERON-GAMMA; LYMPHOCYTE DEPLETION; MICE; MICE, INBRED STRAINS; NEOPLASM STAGING; NEUROBLASTOMA; SPLEEN; SURVIVAL RATE; T-LYMPHOCYTES; T-LYMPHOCYTES, REGULATORY; TIME FACTORS; TRANSCRIPTION FACTORS;

MUS; PROKARYOTA;

EID: 84870156997     PISSN: 16729145     EISSN: 17457270     Source Type: Journal    
DOI: 10.1093/abbs/gms089     Document Type: Article

References (32)

1. Dunn GP, Koebel CM and Schreiber RD. Interferons, immunity and cancer immunoediting. Nat Rev Immunol 2006, 6: 836-848.
2. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 2003, 3: 203-216.
3. Wang B, Zaidi N, He LZ, Zhang L, Kuroiwa JM, Keller T and Steinman RM. Targeting of the non-mutated tumor antigen HER2/neu to mature dendritic cells induces an integrated immune response that protects against breast cancer in mice. Breast Cancer Res 2012, 14: R39.
4. Bao L, Dunham K and Lucas K. MAGE-A1, MAGE-A3, and NY-ESO-1 can be upregulated on neuroblastoma cells to facilitate cytotoxic T lymphocyte-mediated tumor cell killing. Cancer Immunol Immunother 2011, 60: 1299-1307.
5. Seeger RC. Immunology and immunotherapy of neuroblastoma. Semin Cancer Biol 2011, 21: 229-237.
6. Adams GP and Weiner LM. Monoclonal antibody therapy of cancer. Nat Biotechnol 2005, 23: 1147-1157.
7. Sahin U, Tureci O, Schmitt H, Cochlovius B, Johannes T, Schmits R and Stenner F, et al. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci USA 1995, 92: 11810-11813.
8. Sahin U, Tureci O and Pfreundschuh M. Serological identification of human tumor antigens. Curr Opin Immunol 1997, 9: 709-716.
9. Scanlan MJ. Identification of human tumor antigens by serological analysis of recombinant cDNA expression libraries (SEREX). Curr Protoc Immunol 2005, 65: 20.7.1-20.7.19.
10. Yang F, Xiao ZQ, Zhang XZ, Li C, Zhang PF, Li MY and Chen Y, et al. Identification of tumor antigens in human lung squamous carcinoma by serological proteome analysis. J Proteome Res 2007, 6: 751-758.
11. Chen JL, Dunbar PR, Gileadi U, Jager E, Gnjatic S, Nagata Y and Stockert E, et al. Identification of NY-ESO-1 peptide analogues capable of improved stimulation of tumor-reactive CTL. J Immunol 2000, 165: 948-955.
12. Zheng J, Kohler ME, Chen Q, Weber J, Khan J, Johnson BD and Orentas RJ. Serum from mice immunized in the context of Treg inhibition identifies DEK as a neuroblastoma tumor antigen. BMC Immunol 2007, 8: 4.
13. Zheng J, Orentas R, Yan X and Liu H. Humoral immune response induced by an engineered cell-based neuroblastoma vaccine with or without CD25 blockade. Acta Biochim Biophys Sin 2011, 43: 124-132.
14. Zheng J, Jing W and Orentas RJ. Discovery of YB-1 as a new immunological target in neuroblastoma by vaccination in the context of regulatory T cell blockade. Acta Biochim Biophys Sin 2009, 41: 980-990.
15. Guay D, Evoy AA, Paquet E, Garand C, Bachvarova M, Bachvarov D and Lebel M. The strand separation and nuclease activities associated with YB-1 are dispensable for cisplatin resistance but overexpression of YB-1 in MCF7 and MDA-MB-231 breast tumor cells generates several chemoresistance signatures. Int J Biochem Cell Biol 2008, 40: 2492-2507.
16. Lage H, Surowiak P and Holm PS. YB-1 as a potential target in cancer therapy. Pathologe 2008, 29(Suppl. 2): 187-190.
17. Sakaguchi S, Sakaguchi N, Shimizu J, Yamazaki S, Sakihama T, Itoh M and Kuniyasu Y, et al. Immunologic tolerance maintained by CD25\+ CD4\+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev 2001, 182: 18-32.
18. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ and Topalian SL, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002, 298: 850-854.
19. Golgher D, Jones E, Powrie F, Elliott T and Gallimore A. Depletion of CD25\+ regulatory cells uncovers immune responses to shared murine tumor rejection antigens. Eur J Immunol 2002, 32: 3267-3275.
20. Kong M, Fan J, Dong A, Cheng H and Xu R. Effects of polyphyllin I on growth inhibition of human non-small lung cancer cells and in xenograft. Acta Biochim Biophys Sin 2010, 42: 827-833.
21. Hanke P, Rabe C, Serwe M, Bohm S, Pagenstecher C, Sauerbruch T and Caselmann WH. Cirrhotic patients with or without hepatocellular scarcinoma harbour AFP-specific T-lymphocytes that can be activated in vitro by human alpha-fetoprotein. Scand J Gastroenterol 2002, 37: 949-955.
22. Antonia SJ, Mirza N, Fricke I, Chiappori A, Thompson P, Williams N and Bepler G, et al. Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin Cancer Res 2006, 12: 878-887.
23. Loveland BE, Zhao A, White S, Gan H, Hamilton K, Xing PX and Pietersz GA, et al. Mannan-MUC1-pulsed dendritic cell immunotherapy: a phase I trial in patients with adenocarcinoma. Clin Cancer Res 2006, 12: 869-877.
24. Gajewski TF. Identifying and overcoming immune resistance mechanisms in the melanoma tumor microenvironment. Clin Cancer Res 2006, 12: S2326-S2330.
25. Bedognetti D, Balwit JM, Wang E, Disis ML, Britten CM, Delogu LG and Tomei S, et al. SITC/iSBTc cancer immunotherapy biomarkers resource document: online resources and useful tools-a compass in the land of biomarker discovery. J Transl Med 2011, 9: 155.
26. Wachowiak R, Thieltges S, Rawnaq T, Kaifi JT, Fiegel H, Metzger R and Quaas A, et al. Y-box-binding protein-1 is a potential novel tumour marker for neuroblastoma. Anticancer Res 2010, 30: 1239-1242.
27. Fujii T, Yokoyama G, Takahashi H, Namoto R, Nakagawa S, Toh U and Kage M, et al. Preclinical studies of molecular-targeting diagnostic and therapeutic strategies against breast cancer. Breast Cancer 2008, 15: 73-78.
28. Gluz O, Mengele K, Schmitt M, Kates R, Diallo-Danebrock R, Neff F and Royer HD, et al. Y-box-binding protein YB-1 identifies high-risk patients with primary breast cancer benefiting from rapidly cycled tandem highdose adjuvant chemotherapy. J Clin Oncol 2009, 27: 6144-6151.
29. Staveley-O'Carroll K, Sotomayor E, Montgomery J, Borrello I, Hwang L, Fein S and Pardoll D, et al. Induction of antigen-specific T cell anergy: an early event in the course of tumor progression. Proc Natl Acad Sci USA 1998, 95: 1178-1183.
30. Jing W, Orentas RJ and Johnson BD. Induction of immunity to neuroblastoma early after syngeneic hematopoietic stem cell transplantation using a novel mouse tumor vaccine. Biol Blood Marrow Transplant 2007, 13: 277-292.
31. Qin Z and Blankenstein T. CD4\+ T cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells. Immunity 2000, 12: 677-686.
32. Corthay A, Skovseth DK, Lundin KU, Rosjo E, Omholt H, Hofgaard PO and Haraldsen G, et al. Primary antitumor immune response mediated by CD4\+ T cells. Immunity 2005, 22: 371-383.